NEW YORK (GenomeWeb News) – Shares of Exact Sciences today fell as much as 30 percent after the company announced top-line data from a pivotal clinical trial for its colorectal cancer screening test.

Amid heavy trading, shares of the Madison, Wis.-based firm dipped to as low as $6.93 from Wednesday's closing price of $9.97, after results from the trial, called DeeP-C, failed to meet some internal targets.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: gene linked to expansion of the human neocortex, and more.

The National Institute of General Medical Sciences director says changes the agency made have allow it to boost success rates.

Ancient DNA indicates Stone Age, hunter-gather inhabitants of Britain imported wheat.

Joel Achenbach explores at National Geographic why people find science difficult to believe.